Abstract
Glioblastomas are tumors of neuroectodermal origin with a high degree of diversity. Tumor cells isolated from the surgical material of patients with glioblastomas are heterogeneous populations varying in morphology, phenotype, and genetic characteristics. This paper presents a description of two new glioblastoma cell lines, R1 and T2, isolated from tumor tissue of patients in 2010. We investigated their morphological and cytochemical cell characteristics and the expression of neuronal, mesenchymal, and endothelial markers, as well as the activity of genes encoding a number of growth factors, extracellular matrix proteins, and intracellular proteins typical for cells of mesenchymal origin. R1 and T2 cell lines are morphologically different. T2 cell line was characterized by the presence of multinuclear cells. In terms of the expression of β-tubulin III, MGMT, and p53 protein, R1 cell line was more heterogeneous than T2. R1 and T2 glioblastoma cell lines also differed in the presence and ratio of cell populations with mesenchymal, neuronal, and endothelial markers. Thus, neuronal markers CD133/2 and CD56 were detected only on R1 cells. Both lines were characterized by high activity of growth factor genes TGFβ1, VEGF, and FGF2(b), lower activity of EGF, and high expression of THBS1 and αSMA genes. However, the activity of most of the genes under study in R1 cells was higher than in T2 cells. The greatest difference lay in the expression of HGF, FAP, and TNC. Comparison of two new glioblastoma cell lines, R1 and T2, with the continuously cultivated lines А172 and T98G showed that R1 line had remarkable similarity with A172, while T2 glioblastoma resembled T98G cells. Apparently, the differences between R1 and T2 cell lines are determined by the properties of the initial tumors rather than the time of the cell cultivation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- FCS:
-
fetal calf serum
- dNTP:
-
deoxynucleoside triphosphates
- EGF:
-
epidermal growth factor
- FAP:
-
fibroblast activation protein
- bFGF2:
-
basic fibroblast growth factor 2
- GAPDH:
-
glyceraldehyde-3-phosphate dehydrogenase
- GFAP:
-
glial fibrillary acidic protein
- HGF:
-
hepatocyte growth factor
- MGMT:
-
O6-methylguanine-DNA-methyltransferase
- αSMA:
-
smooth muscle actin α2
- TGFβ1:
-
transforming growth factor β1
- THBS1:
-
thrombosponin-1
- TNC:
-
tenascin C
- VEGF:
-
vascular endothelial growth factor.
References
Kiseleva, L.N., Kartashev, A.V., Vartanyan, N.L., Pinevich, A.A., and Samoilovich, M.P., Characteristics of A172 and T98G cell lines, Cell Tissue Biol., 2016, vol. 10, no. 5, pp. 341–348.
Kohno, M., Hasegawa, H., Miyake, M., Yamamoto, T., and Fujita, S., CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase, Int. J. Cancer, 2002, vol. 97, pp. 336–343.
Melendez, B., Garcia-Claver, A., Ruano, Y., Campos-Martin, Y., de Lope, A.R., Perez-Magan, E., Mur, P., Torres, S., Lorente, M., Velasco, G., and Mollejo, M., Copy number alterations in glioma cell lines, in Glioma. Exploring Its Biology and Practical Relevance, Rijeka: InTech, 2011, pp. 429–448.
Philips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Sariano, R.H., Wu, T.D., Misra, F., Nigro, J.M., Colman, H., Soroceanu, L., Wiliams, P.M., Modrusan, Z., Feuerstein, B.G., and Aldape, K., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell, 2006, vol. 9, pp. 157–173.
Tang, Y., Nakada, M.T., Kesavan, P., McCabe, F., Millar, H., Rafferty, P., Bugelski, P., and Yan, L., Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases, Cancer Res., 2005, vol. 65, pp. 3193–3199.
Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M., O’Kelly, M., Tamayo, P., Weir, B.A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H.S., Hodgson, J.G., James, C.D., Sarkaria, J.N., Brennan, C., Kahn, A., Spellman, P.T., Wilson, R.K., Speed, T.P., Gray, J.W., Meyerson, M., Getz, G., Perou, C.M., and Hayes, D.N., Cancer Genome Atlas Research Network, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, 2010, vol. 17, pp. 98–110.
Yang, M., Yuan, Y., Zhang, H., Yan, M., Wang, S., Feng, F., Ji, P., Li, Y., Li, B., Gao, G., Zhao, J., and Wang, L., Prognostic significance of CD147 in patients with glioblastoma, J. Neurooncol., 2013, vol. 115, pp. 19–26.
Yoshino, A., Ogino, A., Yachi, K., Ohta, T., Fukushima, T., Watanabe, T., Katayama, Y., Okamoto, Y., Naruse, N., Sano, E., and Tsumoto, K., Gene expression profiling predicts response to temozolomide in malignant gliomas, Int. J. Oncol., 2010, vol. 36, pp. 1367–1377.
Zarkoob, H., Taube, J.H., Singh, S.K., Mani, S.A., and Kohandel, M., Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein, PLoS One, 2013, vol. 8, p. e64169.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kiseleva, L.N., Kartashev, A.V., Vartanyan, N.L. et al. Characterization of New Human Glioblastoma Cell Lines. Cell Tiss. Biol. 12, 1–6 (2018). https://doi.org/10.1134/S1990519X18010108
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1990519X18010108